Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 13, 2012, Pages 5034-5039

  Dye, John M ^a   Herbert, Andrew S ^a   Kuehne, Ana I ^a   Barth, James F ^a   Muhammad, Majidat A ^a   Zak, Samantha E ^a   Ortiz, Ramon A ^a   Prugar, Laura I ^a   Pratt, William D ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Hemorrhagic fever virus; Passive antibody; Polyclonal antibody; Therapeutic agent

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; FILOVIRUS INFECTION; FOOD AND DRUG ADMINISTRATION; IMMUNE RESPONSE; MACACA; MARBURG VIRUS; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIMATE; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CHEMICAL FRACTIONATION; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; MARBURGVIRUS; NEUTRALIZATION TESTS; SPECIES SPECIFICITY; SURVIVAL ANALYSIS;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MACACA; MARBURGVIRUS; PRIMATES;

EID: 84859462127     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1200409109     Document Type: Article

References (31)

1. Kuhn JH, Jahrling PB (2010) Clarification and guidance on the proper usage of virus and virus species names. Arch Virol 155:445-453.
2. Anonymous (1978) Ebola haemorrhagic fever inZaire, 1976. Bull World Health Organ 56:271-293.
3. Anonymous (1978) Ebola haemorrhagic fever inSudan, 1976. Report of a WHO/International Study Team. (Translated from eng). Bull World Health Organ 56:247-270.
4. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI (1984) Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 2:255-256. (Pubitemid 14057078)
5. Jahrling PB, Peters CJ (1984) Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44:528-533. (Pubitemid 14139025)
6. Jahrling PB, Frame JD, Rhoderick JB, Monson MH (1985) Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 79:380-384. (Pubitemid 15062134)
7. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW (2007) Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196(suppl 2):S400-S403. (Pubitemid 351417287)
8. Mupapa K, et al.; International Scientific and Technical Committee (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179(suppl 1):S18-S23. (Pubitemid 29091378)
9. Jahrling PB, et al. (1996) Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 11: 135-140. (Pubitemid 126446186)
10. Krasnianskiĩ VP, et al. (1994) [The isolation of hyperimmune horse serum to the Ebola virus]. Vopr Virusol 39:91-92.
11. Borisevich IV, et al. (1995) [Development and study of the properties of immunoglobulin against Ebola fever]. Vopr Virusol 40:270-273.
12. Mikhaĩlov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskiĩ VP (1994) [The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. Vopr Virusol 39:82-84.
13. Jahrling PB, et al. (1999) Evaluation of immune globulin and recombinant interferonalpha2b for treatment of experimental Ebola virus infections. J Infect Dis 179(suppl 1):S224-S234. (Pubitemid 29091406)
14. Maruyama T, et al. (1999) Ebola virus can beeffectively neutralized by antibody produced in natural human infection. J Virol 73:6024-6030. (Pubitemid 29274889)
15. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76:6408-6412. (Pubitemid 34556338)
16. Oswald WB, et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3:e9.
17. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE (2001) Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 75:4649-4654. (Pubitemid 32381506)
18. Wilson JA, et al. (2000) Epitopes involved inantibody-mediated protection from Ebola virus. Science 287:1664-1666. (Pubitemid 30127770)
19. Geisbert TW, et al. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 362:1953-1958. (Pubitemid 37548417)
20. Hensley LE, et al. (2007) Recombinant human activated protein C for the post-exposure treatment of Ebola hemorrhagic fever. J Infect Dis 196(suppl 2):S390-S399. (Pubitemid 351417286)
21. Geisbert TW, et al. (2007) Marburg virus Angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 196(suppl 2):S372-S381. (Pubitemid 351417284)
22. Feldmann H, et al. (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3:e2.
23. Daddario-DiCaprio KM, et al. (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367:1399-1404.
24. Geisbert TW, et al. (2010) Postexposure treatment of Marburg virus infection. Emerg Infect Dis 16:1119-1122.
25. Geisbert TW, et al. (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82:5664-5668. (Pubitemid 351705275)
26. Geisbert TW, et al. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375:1896-1905.
27. Warren TK, et al. (2010) Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16:991-994.
28. Waldmann TA (2003) Immunotherapy: Past, present and future. Nat Med 9:269-277.
29. Geisbert TW, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347-2370. (Pubitemid 37466478)
30. Slenczka WG (1999) The Marburg virus outbreak of 1967 and subsequent episodes. Curr Top Microbiol Immunol 235:49-75.
31. Dias JM, et al. (2011) A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18:1424-1427.